# Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.

> **NCT06267794** · PHASE2 · COMPLETED · sponsor: **Jorge L Poo** · enrollment: 180 (actual)

## Conditions studied

- Liver Fibrosis
- Cirrhosis, Liver
- Chronic Liver Disease

## Interventions

- **DRUG:** Pirfenidone 1200 mg
- **DRUG:** Pirfenidone 1800 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06267794
- **Lead sponsor:** Jorge L Poo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-26
- **Primary completion:** 2021-12-30
- **Final completion:** 2023-03-24
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06267794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06267794, "Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06267794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*